CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia. For this type of therapy, peripheral (circulating) immune cells are collected and then modified so that they can recognize an antigen, which is a particle present on the surface of a cancer cell. The CD19-CAR T cell product will be manufactured at the St. Jude Children's Research Hospital's Good Manufacturing Practice (GMP) facility. The main purpose of this study is to determine

Trial Details

NCT ID

NCT06847269

Phase

PHASE2

Sponsor

St. Jude Children's Research Hospital

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• Fludarabine
• Cyclophosphamide
• Mesna
• CD19-CAR T cell Infusion

Locations (sample)

• Memphis, Tennessee, United States|35.14953,-90.04898

Key Eligibility Criteria

• CD19+ leukemia\*\* with any of the following:
• Refractory disease (primary or in relapse)
• 2nd or greater relapse
• Any relapse after allogeneic hematopoietic cell transplantation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →